A carregar...
A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario
Hepatocellular carcinoma (HCC) is the fifth most common malignancy across the world. Alongside improvement in local approaches for early stages, the prognosis of patients with advanced disease remains poor. The tyrosine kinase inhibitor sorafenib was the first drug approved for advanced HCC. During...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8055282/ https://ncbi.nlm.nih.gov/pubmed/33884259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S270532 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|